Analysts Offer Predictions for UNCY Q4 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - HC Wainwright issued their Q4 2026 earnings per share estimates for Unicycive Therapeutics in a research report issued on Tuesday, May 27th. HC Wainwright analyst S. Ramakanth expects that the company will post earnings per share of $0.47 for the quarter. HC Wainwright has a "Strong-Buy" rating and a $9.00 price objective on the stock. The consensus estimate for Unicycive Therapeutics' current full-year earnings is ($0.23) per share.

Separately, Guggenheim initiated coverage on shares of Unicycive Therapeutics in a research report on Monday, April 21st. They issued a "buy" rating and a $6.00 target price on the stock.

Unicycive Therapeutics Trading Down 0.3%

UNCY stock traded down $0.00 on Wednesday, hitting $0.59. 759,158 shares of the company's stock traded hands, compared to its average volume of 1,504,858. The stock has a market cap of $70.93 million, a price-to-earnings ratio of -0.61 and a beta of 2.14. Unicycive Therapeutics has a 1-year low of $0.20 and a 1-year high of $0.96. The stock has a fifty day moving average of $0.59 and a 200-day moving average of $0.62.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.09.

Institutional Investors Weigh In On Unicycive Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vivo Capital LLC raised its position in Unicycive Therapeutics by 14.0% in the first quarter. Vivo Capital LLC now owns 11,370,152 shares of the company's stock worth $6,537,000 after purchasing an additional 1,400,000 shares in the last quarter. Nantahala Capital Management LLC lifted its holdings in shares of Unicycive Therapeutics by 268.5% during the fourth quarter. Nantahala Capital Management LLC now owns 10,391,994 shares of the company's stock valued at $8,253,000 after acquiring an additional 7,571,636 shares during the period. Octagon Capital Advisors LP boosted its stake in shares of Unicycive Therapeutics by 16.8% in the 4th quarter. Octagon Capital Advisors LP now owns 10,000,000 shares of the company's stock valued at $7,942,000 after purchasing an additional 1,441,000 shares in the last quarter. Acuta Capital Partners LLC boosted its stake in shares of Unicycive Therapeutics by 16.4% in the 4th quarter. Acuta Capital Partners LLC now owns 2,303,000 shares of the company's stock valued at $1,829,000 after purchasing an additional 323,801 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Unicycive Therapeutics by 30.3% in the 4th quarter. Geode Capital Management LLC now owns 524,487 shares of the company's stock worth $417,000 after purchasing an additional 122,089 shares during the last quarter. Institutional investors and hedge funds own 40.42% of the company's stock.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.